A Physiologically Based Pharmacokinetic Model of Rifampin in Mice
- 1 April 2013
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 57 (4) , 1763-1771
Abstract
One problem associated with regimen-based development of antituberculosis (anti-TB) drugs is the difficulty of a systematic and thorough in vivo evaluation of the large number of possible regimens that arise from consideration of multiple drugs tested together. A mathematical model capable of simulating the pharmacokinetics and pharmacodynamics of experimental combination chemotherapy of TB offers a way to mitigate this problem by extending the use of available data to investigate regimens that are not initially tested. In order to increase the available mathematical tools needed to support such a model for preclinical anti-TB drug development, we constructed a preliminary whole-body physiologically based pharmacokinetic (PBPK) model of rifampin in mice, using data from the literature. Interindividual variability was approximated using Monte Carlo (MC) simulation with assigned probability distributions for the model parameters. An MC sensitivity analysis was also performed to determine correlations between model parameters and plasma concentration to inform future model development. Model predictions for rifampin concentrations in plasma, liver, kidneys, and lungs, following oral administration, were generally in agreement with published experimental data from multiple studies. Sensitive model parameters included those descriptive of oral absorption, total clearance, and partitioning of rifampin between blood and muscle. This PBPK model can serve as a starting point for the integration of rifampin pharmacokinetics in mice into a larger mathematical framework, including the immune response to Mycobacterium tuberculosis infection, and pharmacokinetic models for other anti-TB drugs.Keywords
This publication has 63 references indexed in Scilit:
- Dose-Ranging Comparison of Rifampin and Rifapentine in Two Pathologically Distinct Murine Models of TuberculosisAntimicrobial Agents and Chemotherapy, 2012
- Mouse Model of Necrotic Tuberculosis Granulomas Develops Hypoxic LesionsThe Journal of Infectious Diseases, 2011
- Comparative Studies Evaluating Mouse Models Used for Efficacy Testing of Experimental Drugs against Mycobacterium tuberculosisAntimicrobial Agents and Chemotherapy, 2011
- PA-824 Exhibits Time-Dependent Activity in a Murine Model of TuberculosisAntimicrobial Agents and Chemotherapy, 2011
- A multifaceted approach to modeling the immune response in tuberculosisWIREs Mechanisms of Disease, 2010
- Tuberculosis research: Going forward with a powerful “Translational Systems Biology” approachTuberculosis, 2010
- Population Modeling and Monte Carlo Simulation Study of the Pharmacokinetics and Antituberculosis Pharmacodynamics of Rifampin in LungsAntimicrobial Agents and Chemotherapy, 2009
- Enhanced Bactericidal Activity of Rifampin and/or Pyrazinamide When Combined with PA-824 in a Murine Model of TuberculosisAntimicrobial Agents and Chemotherapy, 2008
- Population Pharmacokinetics of Rifampin in Pulmonary Tuberculosis Patients, Including a Semimechanistic Model To Describe Variable AbsorptionAntimicrobial Agents and Chemotherapy, 2008
- A model on the influence of age on immunity to infection with Mycobacterium tuberculosisExperimental Gerontology, 2008